Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is an antihistamine with a benzimidazole structure.
Indicated in the treatment of allergic rhinitis and conjunctivitis.
Ophthalmic administration in eye drops or oral in two daily doses.
It is excreted in human milk in clinically insignificant amounts and no short-term or long-term problems have been observed in an infant whose mother took 2 mg once daily (Saito 2020).
The small dose and poor plasma absorption of most topical ophthalmological preparations make it unlikely that significant amounts will transfer into breastmilk.
The small dose and poor plasma absorption of most topical ophthalmological preparations make it unlikely that significant amounts will transfer into breast milk.
Ophthalmic use of emedastine usually does not produce measurable plasma concentrations: following ophthalmic administration of emedastine, plasma drug concentrations were between 0.3 and 0.5 ng / ml or were below the limit of quantification, 0.3 ng / ml (EMA 2009).